Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) traded up 21.1% on Thursday . The stock traded as high as $12.97 and last traded at $12.86, with a volume of 516,907 shares traded. The stock had previously closed at $10.62.

Several brokerages have commented on AQXP. Canaccord Genuity reiterated a “buy” rating and set a $22.00 target price on shares of Aquinox Pharmaceuticals in a research note on Wednesday, August 17th. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Jefferies Group increased their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research note on Friday, August 5th. Finally, Needham & Company LLC began coverage on Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They set a “buy” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $19.86.

The stock’s market cap is $209.45 million. The firm’s 50-day moving average is $8.81 and its 200-day moving average is $8.39.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.22. Equities analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.08) earnings per share for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.